SCHEMBL4258956

SCHEMBL4258956

Cc1ccc(C(=O)N(C)Cc2c(-c3ccc(C)cc3)nc3ccc(C)cn23)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 5/20 0.65
GABRB2 P47870 5/20 0.65
ALB P02768 2/20 0.65
OPRK1 P41145 2/20 0.65
KCNH2 Q12809 2/20 0.65
KDM4E B2RXH2 1/20 0.65
LMNA P02545 1/20 0.65
CYP3A4 P08684 1/20 0.65
CHRM1 P11229 1/20 0.65
HPGD P15428 1/20 0.65
GABRB1 P18505 1/20 0.65
GABRG2 P18507 1/20 0.65
GABRB3 P28472 1/20 0.65
GABRA3 P34903 1/20 0.65
ADRA1A P35348 1/20 0.65
HTR2B P41595 1/20 0.65
GABRA2 P47869 1/20 0.65
HSD17B10 Q99714 1/20 0.65
ALDH1A1 P00352 1/20 0.48
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258326 0.94 GABRA1 (0.59) GABRA1GABRB2ALBOPRK1KCNH2
SCHEMBL4265752 0.94 GABRA1 (0.58) GABRA1GABRB2ALBOPRK1KCNH2
SCHEMBL4265947 0.93 GABRA1 (0.60) GABRA1GABRB2ALBOPRK1KCNH2
SCHEMBL4255836 0.93 GABRA1 (0.57) GABRA1GABRB2ALBOPRK1KCNH2
SCHEMBL4254710 0.92 GABRA1 (0.56) GABRA1GABRB2ALBOPRK1KCNH2
SCHEMBL4260189 0.91 GABRA1 (0.55) GABRA1GABRB2ALBOPRK1KCNH2
SCHEMBL13970054 0.86 GABRA1 (0.54) GABRA1GABRB2ALBOPRK1KCNH2
SCHEMBL4255839 0.86 GABRA1 (0.54) GABRA1GABRB2ALBOPRK1KCNH2
SCHEMBL4257299 0.85 GABRA1 (0.61) GABRA1GABRB2ALBOPRK1KCNH2
SCHEMBL4257119 0.84 GABRA1 (0.60) GABRA1GABRB2ALBOPRK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814880-B1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO FERRER INT (ES) 2009-01-28 EP disclosed
US-20080200473-A1 Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto FERRER INTERNACIONAL, S.A. (ES) 2008-08-21 US disclosed
US-20080200473-A1 Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto FERRER INTERNACIONAL, S.A. (ES) 2008-08-21 US disclosed
EP-1814880-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO FERRER INTERNACIONAL, S.A. (ES) 2007-08-08 EP disclosed
WO-2006051063-A1 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS, USES AND METHODS RELATED THERETO FERRER INTERNACIONAL S. A. (ES) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200473-A1 Imidazo [1,2-a]Pyridine Compounds, Compositions, Uses and Methods Thereto GABRA1, GABRA2, GABRA3 GABRA1 1/4885GABRB2 5/4885ALB 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.